LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis GBX 381.50 +6.00 (+1.60%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades About Oxford Biomedica Stock (LON:OXB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oxford Biomedica alerts:Sign Up Key Stats Today's Range 375▼ 381.9850-Day Range 327▼ 381.5052-Week Range 164.29▼ 394.50Volume618,627 shsAverage Volume208,724 shsMarket Capitalization£401.87 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 433.33Consensus RatingHold Company OverviewOxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More… Does Elon Musk control the U.S. gov’t? (Ad)Elon has been advising the government to reopen America’s nuclear facilities for years, and now, with the help of Biden’s ADVANCE act, these facilities are once again going back online just as he requested. One company is poised to benefit from America’s nuclear revival like no other. Elon Musk is one of the few people who knows this.Watch this new documentary and you’ll discover what Elon knows, Oxford Biomedica Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScoreOXB MarketRank™: Oxford Biomedica scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingOxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOxford Biomedica has only been the subject of 1 research reports in the past 90 days.Read more about Oxford Biomedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -264.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -264.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OXB. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipOxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth.Read more about Oxford Biomedica's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OXB. News and Social Media1.4 / 5News SentimentN/A News SentimentOxford Biomedica has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.MarketBeat FollowsOnly 1 people have added Oxford Biomedica to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.37% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oxford Biomedica's insider trading history. Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address OXB Stock News HeadlinesOxford BioMedica PLC (OXBDF) (Q2 2024) Earnings Call Transcript Highlights: Strong Revenue ...September 24, 2024 | finance.yahoo.comOxford Biomedica (LON:OXB) Given New GBX 380 Price Target at Deutsche Bank AktiengesellschaftSeptember 24, 2024 | americanbankingnews.comGet Ready for Next Week’s Elon Musk Shock I believe Elon Musk is about to shock the world again next week… When he’s set to unveil his new AI product. I’m hosting a special online strategy session to help you prepare on Monday at 10am ET.October 2, 2024 | InvestorPlace (Ad)Oxford Biomedica plc (OXBDF) Q2 2024 Earnings Call TranscriptSeptember 23, 2024 | seekingalpha.comPositive Signs As Multiple Insiders Buy Oxford Biomedica StockSeptember 16, 2024 | finance.yahoo.comOxford Biomedica to host a free webinar showcasing its AAV expertiseAugust 27, 2024 | uk.finance.yahoo.comOxford Biomedica Regulatory NewsAugust 13, 2024 | lse.co.ukOxford BioMedica plc: Oxford Biomedica - Half Year Trading Update and Notice of Interim ResultsAugust 8, 2024 | finanznachrichten.deSee More Headlines OXB Stock Analysis - Frequently Asked Questions How have OXB shares performed this year? Oxford Biomedica's stock was trading at GBX 220 at the beginning of the year. Since then, OXB stock has increased by 73.4% and is now trading at GBX 381.50. View the best growth stocks for 2024 here. How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF) and Premier Oil (PMO). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OXB CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 433.33 High Stock Price TargetGBX 740 Low Stock Price TargetGBX 180 Potential Upside/Downside+13.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-142,020,000.00 Net Margins-145.98% Pretax MarginN/A Return on Equity-124.66% Return on Assets-12.67% Debt Debt-to-Equity Ratio154.88 Current Ratio2.35 Quick Ratio1.67 Sales & Book Value Annual Sales£97.28 million Price / Sales4.13 Cash FlowGBX 126.89 per share Price / Cash Flow3.01 Book ValueGBX 63 per share Price / Book6.06Miscellaneous Outstanding Shares105,340,000Free FloatN/AMarket Cap£401.87 million OptionableNot Optionable Beta1.09 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (LON:OXB) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.